Metabolome in schizophrenia and other psychotic disorders: A general population-based study

Genome Medicine

Volumn 3, Issue 3, 2011, Pages

  Orešič, Matej ^a   Tang, Jing ^a   Seppänen Laakso, Tuulikki ^a   Mattila, Ismo ^a   Saarni, Suoma E ^b   Saarni, Samuli I ^b,c   Lönnqvist, Jouko ^b,c   Sysi Aho, Marko ^a   Hyötyläinen, Tuulia ^a   Perälä, Jonna ^b   Suvisaari, Jaana ^b  

^a VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMIC ACID; HIGH DENSITY LIPOPROTEIN; LACTIC ACID; NEUROLEPTIC AGENT; PHENYLALANINE; PHOSPHOLIPID; PROLINE; PYRUVIC ACID; TRIACYLGLYCEROL; TYROSINE;

ADULT; AFFECTIVE PSYCHOSIS; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; FEMALE; GAS CHROMATOGRAPHY; HEREDITY; HUMAN; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; LIPIDOMICS; MALE; MASS SPECTROMETRY; MENTAL DISEASE; METABOLOME; PATHOPHYSIOLOGY; POPULATION RESEARCH; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; TIME OF FLIGHT MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; UPREGULATION;

EID: 79953072214     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm233     Document Type: Article

References (65)

1. Üstün TB, Rehm J, Chatterji S, Saxena S, Trotter R, Room R, Bickenbach J. Multiple-informant ranking of the disabling effects of different health conditions in 14 countries. Lancet 1999, 354:111-115.
2. Perälä J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsä E, Pirkola S, Partonen T, Tuulio-Henriksson A, Hintikka J, Kieseppa T, Harkanen T, Koskinen S, Lonnqvist J. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 2007, 64:19-28.
3. Murray RM, Lappin J, Di Forti M. Schizophrenia: from developmental deviance to dopamine dysregulation. Eur Neuropsychopharmacol 2008, 18:S129-S134. 10.1016/j.euroneuro.2008.04.002, 18499406.
4. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003, 60:1187-1192. 10.1001/archpsyc.60.12.1187, 14662550.
5. Lichtenstein P, Yip BH, Björk C, Pawitan Y, Cannon TD, Sullivan PF, Hultman CM. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 2009, 373:234-239. 10.1016/S0140-6736(09)60072-6, 19150704.
6. Goldstein JM, Buka SL, Seidman LJ, Tsuang MT. Specificity of familial transmission of schizophrenia psychosis spectrum and affective psychoses in the New England family study's high-risk design. Arch Gen Psychiatry 2010, 67:458-467. 10.1001/archgenpsychiatry.2010.38, 3049996, 20439827.
7. van Os J, Kapur S. Schizophrenia. Lancet 2009, 374:635-645. 10.1016/S0140-6736(09)60995-8, 19700006.
8. Illig T, Gieger C, Zhai G, Romisch-Margl W, Wang-Sattler R, Prehn C, Altmaier E, Kastenmuller G, Kato BS, Mewes HW, Meitinger T, de Angelis MH, Kronenberg F, Soranzo N, Wichmann HE, Spector TD, Adamski J, Suhre K. A genome-wide perspective of genetic variation in human metabolism. Nat Genet 2010, 42:137-141. 10.1038/ng.507, 20037589.
9. Lenz EM, Bright J, Wilson ID, Hughes A, Morrisson J, Lindberg H, Lockton A. Metabonomics, dietary influences and cultural differences: a 1H NMR-based study of urine samples obtained from healthy British and Swedish subjects. J Pharm Biomed Anal 2004, 36:841-849. 10.1016/j.jpba.2004.08.002, 15533678.
10. Nikkilä J, Sysi-Aho M, Ermolov A, Seppänen-Laakso T, Simell O, Kaski S, Oresic M. Gender dependent progression of systemic metabolic states in early childhood. Mol Syst Biol 2008, 4:e197.
11. Velagapudi VR, Hezaveh R, Reigstad CS, Gopalacharyulu PV, Yetukuri L, Islam S, Felin J, Perkins R, Boren J, Oresic M, Backhed F. The gut microbiota modulates host energy and lipid metabolism in mice. J Lipid Res 2010, 51:1101-1112. 10.1194/jlr.M002774, 20040631.
12. Oresic M, Simell S, Sysi-Aho M, Näntö-Salonen K, Seppänen-Laakso T, Parikka V, Katajamaa M, Hekkala A, Mattila I, Keskinen P, Yetukuri L, Reinikainen A, Lähde J, Suortti T, Hakalax J, Simell T, Hyöty H, Veijola R, Ilonen J, Lahesmaa R, Knip M, Simell O. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J Exp Med 2008, 205:2975-2984. 10.1084/jem.20081800, 2605239, 19075291.
13. van der Greef J, Stroobant P, Heijden R. The role of analytical sciences in medical systems biology. Curr Opin Chem Biol 2004, 8:559-565. 10.1016/j.cbpa.2004.08.013, 15450501.
14. Oresic M. Metabolomics, a novel tool for studies of nutrition, metabolism and lipid dysfunction. Nutr Metab Cardiovasc Dis 2009, 19:816-824. 10.1016/j.numecd.2009.04.018, 19692215.
15. Holmes E, Tsang TM, Huang JT-J, Leweke FM, Koethe D, Gerth CW, Nolden BM, Gross S, Schreiber D, Nicholson JK, Bahn S. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med 2006, 3:e327. 10.1371/journal.pmed.0030327, 1551919, 16933966.
16. Schwarz E, Prabakaran S, Whitfield P, Major H, Leweke FM, Koethe D, McKenna P, Bahn S. High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. J Proteome Res 2008, 7:4266-4277. 10.1021/pr800188y, 18778095.
17. Yao JK, Dougherty GG, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R. Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry 2009, 15:938-953. 10.1038/mp.2009.33, 2953575, 19401681.
18. Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KRR. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry 2007, 12:934-945. 10.1038/sj.mp.4002000, 17440431.
19. Health and functional capacity in Finland: baseline results of the Health 2000 Health Examination Survey (Publication B12/2004). , http://www.ktl.fi/terveys2000/index.uk.html
20. First MB, Anthony JC, Tepper S, Dryman A. Structured Clinical Interview for DSM-IV Axis I Disorders, Research Version, Nonpatient Edition (SCID-I/NP) 1997, New York: Biometrics Research, New York State Psychiatric Institute.
21. Wittchen HU, Pfister H. DIA-X-Interviews: Manual für screening-verfahren und Interview; Interviewheft Längsschnittuntersuchung (DIA-X-Lifetime); Ergänzungsheft (DIAX-Lifetime); Interviewheft Querschnittuntersuchung (DIA-X-12 Monate); Ergänzungsheft (DIA-X-12 Monate); PC-Programm zur Durchführung des Interviews (Längs- und Querschnittuntersuchung) 1997, Frankfurt, Germany: Swets and Zeitlinger.
22. Methodology report: Health 2000 Survey. , http://www.terveys2000.fi/doc/methodologyrep.pdf
23. Definition, diagnosis and classification of diabetes mellitus and its complications (WHO/NCD/NCS/99.2). , http://whqlibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2.pdf
24. Suvisaari J, Perälä J, Saarni S, Härkänen T, Pirkola S, Joukamaa M, Koskinen S, Lönnqvist J, Reunanen A. Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey. Eur Arch Psychiatry Clin Neurosci 2008, 258:129-136. 10.1007/s00406-007-0762-y, 17990051.
25. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497. 10.1001/jama.285.19.2486, 11368702, Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults.
26. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961, 4:561-571.
27. Pluskal T, Castillo S, Villar-Briones A, Oresic M. MZmine 2: Modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinformatics 2010, 11:395. 10.1186/1471-2105-11-395, 2918584, 20650010.
28. Yetukuri L, Katajamaa M, Medina-Gomez G, Seppanen-Laakso T, Vidal-Puig A, Oresic M. Bioinformatics strategies for lipidomics analysis: characterization of obesity related hepatic steatosis. BMC Syst Biol 2007, 1:12. 10.1186/1752-0509-1-12, 17408502.
29. Fraley C, Raftery AE. Model-based methods of classification: Using the mclust software in chemometrics. J Stat Soft 2007, 18:1-13.
30. The R Project for Statistical Computing. , http://www.r-project.org/
31. Kampstra P. Beanplot: a boxplot alternative for visual comparison of distributions. J Stat Soft 2008, 28:1-9.
32. McCulloch CE, Searle SR, Neuhaus JM. Generalized, Linear, and Mixed Models 2008, New York: John Wiley and Sons, 2.
33. Castelo R, Roverato A. Reverse engineering molecular regulatory networks from microarray data with qp-graphs. J Comput Biol 2009, 16:213-227. 10.1089/cmb.2008.08TT, 19178140.
34. Bioconductor. , http://www.bioconductor.org/
35. Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C, Christmas R, Avila-Campilo I, Creech M, Gross B, Hanspers K, Isserlin R, Kelley R, Killcoyne S, Lotia S, Maere S, Morris J, Ono K, Pavlovic V, Pico AR, Vailaya A, Wang PL, Adler A, Conklin BR, Hood L, Kuiper M, Sander C, Schmulevich I, Schwikowski B, Warner GJ, et al. Integration of biological networks and gene expression data using Cytoscape. Nat Protoc 2007, 2:2366-2382. 10.1038/nprot.2007.324, 17947979.
36. Brohee S, Faust K, Lima-Mendez G, Vanderstocken G, van Helden J. Network Analysis Tools: from biological networks to clusters and pathways. Nat Protoc 2008, 3:1616-1629. 10.1038/nprot.2008.100, 18802442.
37. Yamashita T, Yamashita K, Kamimura R. A stepwise AIC method for variable selection in linear regression. Commun Stat Theory Methods 2007, 36:2395-2403.
38. Steuer R, Kurths J, Fiehn O, Weckwerth W. Observing and interpreting correlations in metabolomic networks. Bioinformatics 2003, 19:1019-1026. 10.1093/bioinformatics/btg120, 12761066.
39. Suvisaari JM, Saarni SI, Perälä J, Suvisaari JV, Härkänen T, Lönnqvist J, Reunanen A. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J Clin Psychiatry 2007, 68:1045-1055. 10.4088/JCP.v68n0711, 17685741.
40. Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, Rosenheck RA, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1. Schizophr Res 2008, 101:273-286. 10.1016/j.schres.2007.12.487, 18258416.
41. Kotronen A, Velagapudi VR, Yetukuri L, Westerbacka J, Bergholm R, Ekroos K, Makkonen J, Taskinen MR, Oresic M, Yki-Järvinen H. Saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrations. Diabetologia 2009, 52:684-690. 10.1007/s00125-009-1282-2, 19214471.
42. Kotronen A, Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28:27-38. 10.1161/ATVBAHA.107.147538, 17690317.
43. van Nimwegen LJ, Storosum JG, Blumer RM, Allick G, Venema HW, de Haan L, Becker H, van Amelsvoort T, Ackermans MT, Fliers E, Serlie MJ, Sauerwein HP. Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab 2008, 93:572-577. 10.1210/jc.2007-1167, 18029467.
44. Fernandez-Egea E, Bernardo M, Donner T, Conget I, Parellada E, Justicia A, Esmatjes E, Garcia-Rizo C, Kirkpatrick B. Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br J Psychiatry 2009, 194:434-438. 10.1192/bjp.bp.108.052605, 2703813,2703813, 19407273.
45. Steiner J, Walter M, Guest P, Myint AM, Schiltz K, Panteli B, Brauner M, Bernstein HG, Gos T, Herberth M, Schroeter ML, Schwarz MJ, Westphal S, Bahn S, Bogerts B. Elevated S100B levels in schizophrenia are associated with insulin resistance. Mol Psychiatry 2010, 15:3-4. 10.1038/mp.2009.87, 20029405.
46. Guest PC, Wang L, Harris LW, Burling K, Levin Y, Ernst A, Wayland MT, Umrania Y, Herberth M, Koethe D, van Beveren JM, Rothermundt M, McAllister G, Leweke FM, Steiner J, Bahn S. Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naive schizophrenia patients. Mol Psychiatry 2010, 15:118-119. 10.1038/mp.2009.81, 20098438.
47. Guest PC, Schwarz E, Krishnamurthy D, Harris LW, Leweke FM, Rothermundt M, van Beveren NJ, Spain M, Barnes A, Steiner J, Rahmoune H, Bahn S. Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology 2011,
48. Kirkpatrick B, Miller BJ, Garcia-Rizo C, Fernandez-Egea E, Bernardo M. Is abnormal glucose tolerance in antipsychotic-naive patients with nonaffective psychosis confounded by poor health habits?. Schizophr Bull 2010,
49. Newsholme P, Bender K, Kiely A, Brennan L. Amino acid metabolism, insulin secretion and diabetes. Biochem Soc Trans 2007, 35:1180-1186. 10.1042/BST0351180, 17956307.
50. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Haqq AM, Shah SH, Arlotto M, Slentz CA, Rochon J, Gallup D, Ilkayeva O, Wenner BR, Yancy WS, Eisenson H, Musante G, Surwit RS, Millington DS, Butler MD, Svetkey LP. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009, 9:311-326. 10.1016/j.cmet.2009.02.002, 19356713.
51. Fernstrom JD. Branched-chain amino acids and brain function. J Nutr 2005, 135:1539S-1546.
52. Neuhaus AH, Goldberg TE, Hassoun Y, Bates JA, Nassauer KW, Sevy S, Opgen-Rhein C, Malhotra AK. Acute dopamine depletion with branched chain amino acids decreases auditory top-down event-related potentials in healthy subjects. Schizophr Res 2009, 111:167-173. 10.1016/j.schres.2009.03.023, 19356906.
53. Leung S, Croft R, Guille V, Scholes K, O'Neill B, Phan K, Nathan P. Acute dopamine and/or serotonin depletion does not modulate mismatch negativity (MMN) in healthy human participants. Psychopharmacology 2010, 208:233-244. 10.1007/s00213-009-1723-0, 20012022.
54. Craft S, Stennis Watson G. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 2004, 3:169-178. 10.1016/S1474-4422(04)00681-7, 14980532.
55. Coyle J. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 2006, 26:365-384. 10.1007/s10571-006-9062-8, 16773445.
56. Cherlyn SY, Woon PS, Liu JJ, Ong WY, Tsai GC, Sim K. Genetic association studies of glutamate, GABA and related genes in schizophrenia and bipolar disorder: a decade of advance. Neurosci Biobehav Rev 2010, 34:958-977. 10.1016/j.neubiorev.2010.01.002, 20060416.
57. Smith QR. Transport of glutamate and other amino acids at the blood-brain barrier. J Nutr 2000, 130:1016S-1022S.
58. Liu H, Heath SC, Sobin C, Roos JL, Galke BL, Blundell ML, Lenane M, Robertson B, Wijsman EM, Rapoport JL, Gogos JA, Karayiorgou M. Genetic variation at the 22q11 PRODH2/DGCR6 locus presents an unusual pattern and increases susceptibility to schizophrenia. Proc Natl Acad Sci USA 2002, 99:3717-3722. 10.1073/pnas.042700699, 122590, 11891283.
59. Kempf L, Nicodemus KK, Kolachana B, Vakkalanka R, Verchinski BA, Egan MF, Straub RE, Mattay VA, Callicott JH, Weinberger DR, Meyer-Lindenberg A. Functional polymorphisms in PRODH are associated with risk and protection for schizophrenia and fronto-striatal structure and function. PLoS Genet 2008, 4:e1000252. 10.1371/journal.pgen.1000252, 2573019, 18989458.
60. Raux G, Bumsel E, Hecketsweiler B, van Amelsvoort T, Zinkstok J, Manouvrier-Hanu S, Fantini C, Breviere G-MM, Di Rosa G, Pustorino G, Vogels A, Swillen A, Legallic S, Bou J, Opolczynski G, Drouin-Garraud V, Lemarchand M, Philip N, Gerard-Desplanches A, Carlier M, Philippe A, Nolen MC, Heron D, Sarda P, Lacombe D, Coizet C, Alembik Y, Layet V, Afenjar A, Hannequin D, et al. Involvement of hyperprolinemia in cognitive and psychiatric features of the 22q11 deletion syndrome. Hum Mol Genet 2007, 16:83-91. 10.1093/hmg/ddl443, 17135275.
61. Bender HU, Almashanu S, Steel G, Hu CA, Lin WW, Willis A, Pulver A, Valle D. Functional consequences of PRODH missense mutations. Am J Hum Genet 2005, 76:409-420. 10.1086/428142, 15662599.
62. Guilmatre A, Dubourg C, Mosca AL, Legallic S, Goldenberg A, Drouin-Garraud V, Layet V, Rosier A, Briault S, Bonnet-Brilhault F, Laumonnier F, Odent S, Le Vacon G, Joly-Helas G, David V, Bendavid C, Pinoit JM, Henry C, Impallomeni C, Germano E, Tortorella G, Di Rosa G, Barthelemy C, Andres C, Faivre L, Frebourg T, Saugier Veber P, Campion D. Recurrent rearrangements in synaptic and neurodevelopmental genes and shared biologic pathways in schizophrenia, autism, and mental retardation. Arch Gen Psychiatry 2009, 66:947-956. 10.1001/archgenpsychiatry.2009.80, 2958844, 19736351.
63. Sigurdsson T, Stark KL, Karayiorgou M, Gogos JA, Gordon JA. Impaired hippocampal-prefrontal synchrony in a genetic mouse model of schizophrenia. Nature 2010, 464:763-767. 10.1038/nature08855, 2864584, 20360742.
64. McGrath JJ. The surprisingly rich contours of schizophrenia epidemiology. Arch Gen Psychiatry 2007, 64:14-16. 10.1001/archpsyc.64.1.14, 17199050.
65. Smith M, Hopkins D, Peveler RC, Holt RIG, Woodward M, Ismail K. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2008, 192:406-411. 10.1192/bjp.bp.107.037184, 18515889.